Germany's independent vaccine committee has formally approved giving the AstraZeneca shot to people age 65 and over, the health minister said Thursday.
The decision was good news for older people who are waiting for a vaccination," said the minister, Jens Spahn. "They will get vaccinated faster.
The vaccine made by British-Swedish company AstraZeneca is one of three authorized for use in the 27-nation European Union. But several countries, including Germany, initially restricted it to people under 65, or in some cases under 55, citing a lack of data on its effectiveness in older people.
But the publication of data and pressure to speed up the EU's slow vaccine rollout has prompted authorities across the bloc to revise their guidance.
The independent committee, known by its German acronym StiKo, also advised waiting 12 weeks between administering the first and second AstraZeneca shots, as studies show this increases the vaccine's effectiveness, Spahn said.
He said both recommendations will be swiftly incorporated in Germany's vaccine rules, which the government announced late Wednesday would be overhauled to allow more people to get the shots sooner.
Restrictive rules and a rush of deliveries mean Germany is sitting on a stockpile of more than 2 million doses of the AstraZeneca vaccine even as many who want it can't get the shots.
France, Belgium and Italy already loosened their age restrictions for the AstraZeneca vaccine earlier this week as they scramble to confront a looming third spike in COVID-19 cases driven by more contagious virus variants.
Data published this week from England's mass vaccination program showed that both the AstraZeneca and the Pfizer-BioNTech vaccines were around 60% effective in preventing symptomatic COVID-19 in people over 70 after just a single dose.
The analysis released by Public Health England, which hasn't been peer reviewed yet, also showed that both vaccines were about 80% effective in preventing hospitalizations among people over 80.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.